Welcome, visitor! [ Register | Login rss Google+ facebook twitter LinkedIn Pinterest

Daiichi Sankyo, Inc. – Pharmaceutical treatment of hypertension, dyslipidemia and others

  • Company: Daiichi Sankyo, Inc.
  • Street: Two Hilton Court
  • City/Town/Village: Parsippany
  • State/Prefecture: New Jersey
  • Country: United States
  • Zip/Postal Code: 07054
  • Phone: 973-944-2600
  • Website: http://dsi.com
  • Contact: http://dsi.com/web/dsi/contact-us1
  • Listed: 05/21/2014 4:17 pm
  • Expires: This ad has expired
Daiichi Sankyo, Inc. – Pharmaceutical treatment of hypertension, dyslipidemia and others

Daiichi Sankyo, Inc. is the U.S. headquarters of Tokyo-based Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group, which spans 56 countries. Established in 2006 from the merger of the Daiichi and Sankyo pharmaceutical companies, Daiichi Sankyo, Inc. currently markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome and metastatic melanoma.

A Legacy of Innovation, 110 Years and Counting
As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability. While the success of our medicines speaks for itself, our corporate mission defines our vision and purpose:

To enrich quality of life around the world through the development of innovative pharmaceuticals.

How do we bring this corporate mission to life? By bringing together medical and scientific expertise, a collaborative and ethical culture, and a robust pipeline. At Daiichi Sankyo, innovation is more than a corporate motto. It’s a philosophy we put into practice each and every day.

Established in 2006 by the merger of two 100-year-old Japanese pharmaceutical companies, Daiichi Sankyo, Inc. inherited a rich legacy of innovation and scientific expertise across therapeutic categories. Today, we’re just as dedicated to improving quality of life for the patients who need our medicines as our founders were a century ago. Our scientific expertise, robust pipeline and collaborative and ethical culture make a world of difference in the lives of patients and employees, and in the communities where we live and work.

Ad Reference ID: 345537d32e41584a

No Tags


One Response to “Daiichi Sankyo, Inc. – Pharmaceutical treatment of hypertension, dyslipidemia and others”

  1. Sanford-Burnham and Daiichi Sankyo team up to develop treatment of cardiovascular-metabolic diseases

    Orlando, Fla., U.S. and Tokyo, Japan(May 21, 2014) – Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

    Continue reading »

Leave a Reply

To inquire about this ad listing, complete the form below to send a message to the ad poster.

Group Sites

  • Ad 1
  • Ad 2
  • Ad 3
  • Ad 4